Newsroom

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 4, 2019– AVEO Oncology (NASDAQ: AVEO) today announced that previously reported data from its Phase 3 TIVO-3 study were published in The Lancet Oncology. TIVO-3 is the Company’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA®), the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), to sorafenib in 350 subjects

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 26, 2019– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 31st Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December 3, 2019 at 4:30 p.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 19, 2019– AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Scarlett Spring to its Board of Directors. Ms. Spring brings to AVEO extensive sales, commercial, and leadership experience in the biopharmaceutical and life sciences industries. “It is a pleasure to welcome Scarlett to our Board of Directors,” said Michael Bailey, president and chief executive officer of AVEO. “Her

Download PDF – Tivozanib Significantly Improves PFS and ORR Compared to Sorafenib and Demonstrates Updated Interim OS HR of 0.99 in Refractory Advanced RCC – – Outcomes Favor Tivozanib in Patients Previously Treated With Checkpoint Inhibitors as Well as Two VEGFR-TKIs – – Data Featured in Oral Presentation at the 18th International Kidney Cancer Symposium – CAMBRIDGE,

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 12, 2019– AVEO Oncology (NASDAQ: AVEO) today reported financial results for the third quarter ended September 30, 2019 and provided a business update. “This quarter we have made meaningful progress toward our goal of bringing effective and better tolerated therapies to patients battling kidney and other cancers,” said Michael Bailey, president and chief executive officer of AVEO.

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 7, 2019– AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the initiation of the CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with high-dose cytarabine vs. high-dose cytarabine alone in patients with relapsed and refractory acute myeloid leukemia (AML). AVEO will

Download PDF – NDA Filing Planned for 1Q20 for Relapsed/Refractory RCC – – Company Plans Final OS Analysis in 2Q20 – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 4, 2019– AVEO Oncology (NASDAQ: AVEO) today provided a regulatory update following a meeting with the U.S. Food and Drug Administration (FDA) to discuss results from the August 2019 overall survival (OS) analysis of the TIVO-3 trial and the

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 30, 2019– AVEO Oncology (NASDAQ: AVEO) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical trial evaluating FOTIVDA® (tivozanib), the Company’s once-daily, potent and selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in combination with IMFINZI® (durvalumab), AstraZeneca’s human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in